Triazole agonists of the APJ receptor

US9656997B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Ning Chen · Thousand Oaks, US
• Xiaoqi Chen · Palo Alto, US
• Alan C. Cheng · Cambridge, US
• Richard V. Connors · Mesa, US
• Jeffrey Deignan · San Francisco, US
• Paul John Dransfield · Arlington, US
• Xiaohui Du · Foster City, US
• Zice Fu · Foster City, US
• Julie Anne Heath · Chico, US
• Daniel B. Horne · Natick, US
• Jonathan Houze · Cambridge, US
• Matthew R. Kaller · Ventura, US
• David John Kopecky · West Hollywood, US
• Su-Jen Lai · Somerville, US
• Zhihua Ma · Lexington, US
• Lawrence R. McGee · Pacifica, US
• Julio C. Medina · Redwood City, US
• Jeffrey T. Mihalic · San Francisco, US
• Nobuko Nishimura · Calabasas, US
• Steven H. Olson · Millbrae, US
• Vatee Pattaropong · Bedford, US
• Gayathri Swaminath · Brisbane, US
• Xiaodong Wang · Zhejiang, CN
• Kevin Yang · San Gabriel, US
• Mikkel V. Debenedetto · Shrewsbury, US
• Robert P. Farrell · Thousand Oaks, US
• Simon J. Hedley · Thousand Oaks, US
• Ted Judd · San Fernando, US
• Frank Kayser · San Francisco, US

Key dates

• Filing date: Oct 19, 2016
• Grant date: May 23, 2017
• Expiry date: Oct 19, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/07
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures:where the definitions of the variables are provided herein.